Aurinia Pharmaceuticals Inc (AUPH)vsAstraZeneca PLC (AZN)
AUPH
Aurinia Pharmaceuticals Inc
$16.21
0.00%
HEALTHCARE · Cap: $2.17B
AZN
AstraZeneca PLC
$185.48
-0.59%
HEALTHCARE · Cap: $293.73B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 19290% more annual revenue ($62.38B vs $321.74M). AUPH leads profitability with a 97.7% profit margin vs 17.7%. AUPH trades at a lower P/E of 7.1x. AZN earns a higher WallStSmart Score of 68/100 (B-).
AUPH
Buy59
out of 100
Grade: C
AZN
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AUPH.
Margin of Safety
+4.3%
Fair Value
$197.94
Current Price
$185.48
$12.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 98 of every $100 in revenue as profit
Strong operational efficiency at 51.6%
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 29.6%
Earnings expanding 23.5% YoY
Generating 4.0B in free cash flow
Areas to Watch
0.0% earnings growth
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 97.7% and operating margin at 51.6%. Revenue growth of 13.9% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bear Case : AUPH
The primary concerns for AUPH are EPS Growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
AUPH carries more volatility with a beta of 1.34 — expect wider price swings.
AUPH is growing revenue faster at 13.9% — sustainability is the question.
AZN generates stronger free cash flow (4.0B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (68/100 vs 59/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?